Targets › LAT1
1 program from 1 company in 1 trial: 1 Phase 2; Psychiatry; next expected readout Jun 2028.
Forms a heterodimer with SLC3A2 that functions as a sodium-independent transporter for large neutral amino acids. Functions as an obligatory amino acid antiporter, mediating the exchange of amino acids and amino acid-related compounds across the plasma membrane. (UniProt, Q01650)
Open in Phaseline: the race on LAT1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Emory University | L-leucine Competitive inhibitor of kynurenine uptake into the brain via large neutral amino acid tra | LAT1 | Phase 2 | Major Depression | Jun 2028 |
Major Depression (1)
small molecule (1)
Emory University (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.